Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Net Assets
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has net assets worth CN¥6.14 Billion CNY (≈ $898.26 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.50 Billion ≈ $1.54 Billion USD) and total liabilities (CN¥4.36 Billion ≈ $638.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Heilongjiang ZBD Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.14 Billion |
| % of Total Assets | 58.46% |
| Annual Growth Rate | 14.68% |
| 5-Year Change | -10.95% |
| 10-Year Change | 45.8% |
| Growth Volatility | 24.19 |
Heilongjiang ZBD Pharmaceutical Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 603567 market cap overview.
Annual Net Assets for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual net assets of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2025. Also explore 603567 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.28 Billion ≈ $918.84 Million |
-24.27% |
| 2024-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
+3.11% |
| 2023-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
+13.14% |
| 2022-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+0.79% |
| 2021-12-31 | CN¥7.05 Billion ≈ $1.03 Billion |
+28.13% |
| 2020-12-31 | CN¥5.50 Billion ≈ $805.28 Million |
+4.82% |
| 2019-12-31 | CN¥5.25 Billion ≈ $768.26 Million |
+5.36% |
| 2018-12-31 | CN¥4.98 Billion ≈ $729.21 Million |
+6.50% |
| 2017-12-31 | CN¥4.68 Billion ≈ $684.71 Million |
+8.65% |
| 2016-12-31 | CN¥4.31 Billion ≈ $630.20 Million |
+8.16% |
| 2015-12-31 | CN¥3.98 Billion ≈ $582.63 Million |
+83.26% |
| 2014-12-31 | CN¥2.17 Billion ≈ $317.92 Million |
+24.36% |
| 2013-12-31 | CN¥1.75 Billion ≈ $255.64 Million |
+32.43% |
| 2012-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
+42.91% |
| 2011-12-31 | CN¥923.09 Million ≈ $135.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Heilongjiang ZBD Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 917.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.55 Billion | 40.64% |
| Other Components | CN¥3.73 Billion | 59.36% |
| Total Equity | CN¥6.28 Billion | 100.00% |
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
$759.08 Million |
|
Barclays PLC
LSE:BARC
|
$759.09 Million |
|
Innova Captab Limited
NSE:INNOVACAP
|
$759.16 Million |
|
Shenzhen Jinjia Color Printing Group Co Ltd
SHE:002191
|
$759.36 Million |
|
Southern Cable Group Bhd
KLSE:0225
|
$757.79 Million |
|
Chief Telecom Inc
TWO:6561
|
$757.69 Million |
|
Shenzhen Grandland Decoration Group Co Ltd
SHE:002482
|
$757.46 Million |
|
Obsidian Energy Ltd
TO:OBE
|
$757.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heilongjiang ZBD Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,800,611,827 to 6,280,907,362, a change of -1,519,704,465 (-19.5%).
- Net loss of 1,366,528,672 reduced equity.
- Dividend payments of 276,560,034 reduced retained earnings.
- Other comprehensive income decreased equity by 4,985,730.
- Other factors increased equity by 128,369,971.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.37 Billion | -21.76% |
| Dividends Paid | CN¥276.56 Million | -4.4% |
| Other Comprehensive Income | CN¥-4.99 Million | -0.08% |
| Other Changes | CN¥128.37 Million | +2.04% |
| Total Change | CN¥- | -19.48% |
Book Value vs Market Value Analysis
This analysis compares Heilongjiang ZBD Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.31x to 0.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.28 | CN¥5.51 | x |
| 2012-12-31 | CN¥1.82 | CN¥5.51 | x |
| 2013-12-31 | CN¥2.42 | CN¥5.51 | x |
| 2014-12-31 | CN¥3.04 | CN¥5.51 | x |
| 2015-12-31 | CN¥5.20 | CN¥5.51 | x |
| 2016-12-31 | CN¥5.07 | CN¥5.51 | x |
| 2017-12-31 | CN¥5.50 | CN¥5.51 | x |
| 2018-12-31 | CN¥5.86 | CN¥5.51 | x |
| 2019-12-31 | CN¥6.17 | CN¥5.51 | x |
| 2020-12-31 | CN¥6.47 | CN¥5.51 | x |
| 2021-12-31 | CN¥8.15 | CN¥5.51 | x |
| 2022-12-31 | CN¥7.54 | CN¥5.51 | x |
| 2023-12-31 | CN¥8.03 | CN¥5.51 | x |
| 2024-12-31 | CN¥8.30 | CN¥5.51 | x |
| 2025-12-31 | CN¥6.67 | CN¥5.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heilongjiang ZBD Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -171.23%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.69x
- Recent ROE (-21.76%) is below the historical average (11.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 32.07% | 27.64% | 0.74x | 1.56x | CN¥203.75 Million |
| 2012 | 29.68% | 28.24% | 0.65x | 1.62x | CN¥258.37 Million |
| 2013 | 24.97% | 30.88% | 0.44x | 1.86x | CN¥261.94 Million |
| 2014 | 21.81% | 29.96% | 0.44x | 1.65x | CN¥258.45 Million |
| 2015 | 14.62% | 28.23% | 0.35x | 1.49x | CN¥185.01 Million |
| 2016 | 11.85% | 21.31% | 0.37x | 1.49x | CN¥79.44 Million |
| 2017 | 11.15% | 16.61% | 0.46x | 1.47x | CN¥53.93 Million |
| 2018 | 9.30% | 16.63% | 0.34x | 1.65x | CN¥-34.82 Million |
| 2019 | 7.80% | 12.41% | 0.37x | 1.72x | CN¥-115.58 Million |
| 2020 | 7.94% | 12.82% | 0.33x | 1.86x | CN¥-113.16 Million |
| 2021 | 4.72% | 8.05% | 0.36x | 1.63x | CN¥-372.19 Million |
| 2022 | 2.61% | 4.40% | 0.36x | 1.64x | CN¥-524.45 Million |
| 2023 | 6.26% | 15.06% | 0.25x | 1.65x | CN¥-282.10 Million |
| 2024 | 5.62% | 16.21% | 0.21x | 1.63x | CN¥-341.84 Million |
| 2025 | -21.76% | -171.23% | 0.08x | 1.69x | CN¥-1.99 Billion |
Industry Comparison
This section compares Heilongjiang ZBD Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,877,324,223
- Average return on equity (ROE) among peers: 8.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heilongjiang ZBD Pharmaceutical Co Ltd (603567) | CN¥6.14 Billion | 32.07% | 0.71x | $758.10 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $589.07 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $422.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $2.46 Billion | 15.95% | 0.27x | $4.31 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 10.59% | 0.88x | $2.30 Billion |
| Wedge Industrial Co Ltd (000534) | $1.41 Billion | 5.42% | 0.68x | $1.73 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $32.60 Million | 12.25% | 0.82x | $13.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.54 Billion | 7.70% | 0.92x | $945.43 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $380.02 Million | 7.98% | 0.67x | $320.64 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $1.01 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.11 Billion |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the pharmaceuticals business in China. The company researches, develops, produces, and sale traditional Chinese medicine preparations, biological agents, and chemical agents, as well as involved in the pharmaceutical and Chinese medicinal materials trade; and leasing business. It also engages in pharmaceutical manufacturing; contract manufactur… Read more